In addition, metformin inhibits NLRP3 inflammasome activation and alveolar macrophage production of interleukin-IL-1β, as well as inflammasome independent IL-6 secretion, thereby reducing lipopolysaccharide (LPS) and SARS-CoV-2-induced ARDS. This evidence concerns the gene IL6 and acute respiratory distress syndrome.